Study authors tested the effect of disinfectant wipes on spore loads and cross-contamination risk for Clostridioides difficile.
Publication of the revised clinical practice guidelines for Clostridioides difficile infection was followed by significant increases in use of oral vancomycin and fidaxomicin, and a significant decrease in use of oral metronidazole.
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.
As a result of a decline in healthcare–associated infections, the estimated burden of Clostridioides difficile infection in the United States decreased by an adjusted 24% from 2011 through 2017.
From 2011 to 2017, there was a decrease in the estimated national burden of Clostridium difficile infection.
Features of fecal microbiota at baseline and after antibiotic therapy may be predictive of recurrent Clostridiodes difficile infection in patients with and without ulcerative colitis.
A glutamate dehydrogenase test for Clostridioides difficile may reduce unnecessary isolation time for patients.
The FDA has approved fidaxomicin for the treatment of Clostridioides difficile-associated diarrhea in adult and pediatric patients aged 6 months and older.
Clostridioides difficile infection is associated with a large burden on the healthcare system in the United States.
Dual therapy with intravenous metronidazole and oral vancomycin is not superior to oral vancomycin alone in the treatment of Clostridioides difficile infections.
Asymptomatic carriers of C. difficile at significant risk for progression to symptomatic infection
Toxin enzyme immunoassay more accurately identifies severe C difficile infections from strains more likely to cause recurrence, but otherwise had similar results for complications and mortality compared with the standard nucleic acid amplification test.
Patients with recurrent Clostridioides difficile infection (CDI) were less likely to develop bloodstream infections (BSI) if treated with fecal microbiota transplantation (FMT) compared with antibiotics.
Studies present promising therapeutic options to reduce recurrent CDI, as well as strategies to improve favorable economic outcomes.
Detection of Clostridioides difficile toxins in fecal matter can lead to accurate diagnosis of C difficile infection.
Direct costs come from extended length of stay and increased hospitalization costs
Repeat testing of nucleic acid amplification tests is not recommended for detection of the presence of Clostridioides (formerly Clostridium) difficile in adults.
The use of a nucleic acid assay (NAAT) for diagnosing Clostridium difficile infection demonstrated a significant reduced length of stay (LOS) for patients compared with a multi-step enzyme immunoassay-based strategy, according to data presented at the American Society for Microbiology (ASM) Microbe 2019, held in San Francisco, California, from June 20 to 24, 2019. C…
Fecal microbiota transplantation is a still-experimental procedure, as yet unapproved by the FDA
Facility-level rates of hospital-onset Clostridioides difficile infection have been found to decrease correspondingly with lower usage of antibiotics.